ErringtonACStöhrTHeersCLeesG. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol. 2008;73:157-169.
2.
GoodwinHHinsonHEShermockKMKaranjiaNLewinJJ3rd. The use of lacosamide in refractory status epilepticus. Neurocrit Care. 2011;14:348-353.
3.
ChungSSperlingMRBitonV; SP754 Study Group. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia. 2010;51:958-967.
4.
Ben-MenachemEBitonVJatuzisDAbou-KhalilBDotyPRuddGD. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia. 2007;48:1308-1317.
5.
HalászP1KälviäinenRMazurkiewicz-BeldzińskaM. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia. 2009;50:443-453.
6.
MiroJToledoMSantamarinaE. Efficacy of intravenous lacosamide as an add-on treatment in refractory status epilepticus: a multicentric prospective study. Seizure. 2013;22:77-79.
7.
ZouYSVan DykeDLThorlandEC. Mosaic ring 20 with no detectable deletion by FISH analysis: characteristic seizure disorder and literature review. Am J Med Genet. 2006;140:1696-1706.
8.
WalleighDJLegidoAValenciaI. Ring chromosome 20: a pediatric potassium channelopathy responsive to treatment with ezogabine. Pediatr Neurol. 2013;49:368-369.
9.
JacobsJBernardGAndermannEDubeauFAndermannF. Refractory and lethal status epilepticus in a patient with ring chromosome 20 syndrome. Epileptic Disord. 2008;10:254-259.
10.
Gonzalez-DelgadoMSalasJHernandoICallejaSHernandezC. Ring chromosome 20: a distinctive syndrome identifiable by electroclinical diagnosis [in Spanish]. Neurologia. 2004;19:215-219.
11.
ElensIVanrykelKDe WaeleLJansenK. Ring chromosome 20 syndrome: electroclinical description of six patients and review of the literature. Epilepsy Behav. 2012;23:409-414.
